Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL7149550

CC(C)(C)c1cccc(C(C)(C)C)n1.O=S(=O)(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGK1 P00558 1/20 0.44
PGK2 P07205 1/20 0.44
HSD11B1 P28845 4/20 0.38
ACHE P22303 1/20 0.36
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CA2 P00918 2/20 0.35
CA1 P00915 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
MMP13 P45452 1/20 0.35
P2RX7 Q99572 1/20 0.34
PTPN1 P18031 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
BRS3 P32247 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1550855 0.81 PGK1 (0.38) PGK1PGK2HSD11B1ALDH1A1LMNA
Trifluoromethanesulfonic Acid SCHEMBL6282631 0.80 SMN1; SMN2 (0.46) HSD11B1ALDH1A1LMNASMN1; SMN2L3MBTL1
Trifluoromethanesulfonic Acid SCHEMBL3488688 0.79 SDHB (0.36) PGK1PGK2ALDH1A1LMNAGAA
SCHEMBL42955 0.78 PGK1 (0.39) PGK1PGK2ALDH1A1LMNAGAA
SCHEMBL12553835 0.77 PGK1 (0.42) PGK1PGK2ACHETSHRCA2
SCHEMBL2609323 0.77 IDH1 (0.49) PGK1PGK2P2RX7KDM4E
Iodide SCHEMBL2346492 0.76 PGK1 (0.38) PGK1PGK2ALDH1A1LMNAGAA
Hydrochloric Acid SCHEMBL30595152 0.76 PGK1 (0.38) PGK1PGK2ALDH1A1LMNAGAA
Trifluoromethanesulfonic Acid SCHEMBL28461783 0.76 HSD11B1 (0.44) HSD11B1ALDH1A1GAAP2RX7KDM4E
SCHEMBL28748272 0.74 PGK1 (0.39) PGK1PGK2ACHEALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119823196-A Glycoside and preparation method thereof 南开大学 2025-04-15 CN claimed
CN-119823196-A Glycoside and preparation method thereof 南开大学 2025-04-15 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed
US-5830969-A ANHYDROUS MIXTURE CONTAINING LEWIS BASE DOW CORNING CORPORATION (US) 1998-11-03 US disclosed
EP-0854162-A2 Silyl ester initiators for ring opening polymerization of cyclosiloxanes DOW CORNING CORPORATION (US) 1998-07-22 EP disclosed
US-5696219-A Silyl ester initiators for cyclosiloxane ring opening polymerization DOW CORNING CORPORATION (US) 1997-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 PGK1 2651/4885PGK2 2863/4885HSD11B1 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.